ETTX News and Press, Entasis Therapeutics Holdings Inc. From 04/22/20

WALTHAM, Mass., April 22, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that it has completed the init...

New York City, NY:March 26, 2020 – Published via (Wired Release) – Recent Research and Future Market Potential of Acinetobacter Infections Treatment Market in Global Industry: 2020 Research and New Innovations in Pharmaceuticals and Healthcare Sector. The prime objective of the r...

Gainers:  USD Partners (NYSE: USDP )  +127% . More news on: USD Partners LP, Guess', Inc., Harvest Capital Credit Corp., Stocks on the move, , Read more ...

Entasis Therapeutics (NASDAQ: ETTX ): FY GAAP EPS of -$3.33 misses by $0.40 . More news on: Entasis Therapeutics Holdings Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

WALTHAM, Mass., March 11, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced its full year 2019 financial results and business highlights. ...

Entasis Therapeutics (NASDAQ: ETTX ): Q3 GAAP EPS of -$0.27. Revenue of $7M Press Release More news on: Entasis Therapeutics, Earnings news and commentary, Healthcare stocks news, ,

WALTHAM, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced its third quarter financial results for the period ended Septem...

WALTHAM, Mass., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel precision antibacterials to treat serious drug-resistant infections, today announced the appointment of David Altarac, M.D., MPA a...

WALTHAM, Mass., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Michael Gutch, Chief Business Officer and Chief ...

WALTHAM, Mass., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel precision antibacterials to treat serious drug-resistant infections, today announced its participation in an industry panel presen...